Interleukin-18 (IL-18) Enhances Innate IL-12-Mediated Resistance to Toxoplasma gondii

GUIFANG CAI,1 ROBERT KASTELEIN,2 AND CHRISTOPHER A. HUNTER 1*

Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, 1 and Department of Molecular Biology, DNAX Research Institute, Palo Alto, California

Received 17 March 2000/Returned for modification 10 May 2000/Accepted 28 August 2000

Innate resistance to Toxoplasma gondii is dependent on the ability of interleukin-12 (IL-12) to stimulate natural killer (NK) cell production of gamma interferon (IFN-γ). Since IL-18 is a potent enhancer of IL-12-induced production of IFN-γ by NK cells, SCID mice (which lack an adaptive immune response) were used to assess the role of IL-18 in innate resistance to T. gondii. Administration of anti-IL-18 to SCID mice infected with T. gondii resulted in an early reduction in serum levels of IFN-γ but did not significantly decrease resistance to this infection. In contrast, administration of exogenous IL-18 to infected SCID mice resulted in increased production of IFN-γ, reduced parasite burden, and a delay in time to death. The protective effects of IL-18 treatment correlated with increased NK cell numbers and cytotoxic activity at the local site of administration and with elevated levels of inducible nitrous oxide synthase in the spleens of treated mice. In addition, in vivo depletion studies demonstrated that although endogenous IL-18 appears to have a limited role in innate resistance to T. gondii, treatment with IL-18 can augment NK cell-mediated immunity to this pathogen.

Interleukin-18 (IL-18) is a cytokine which was identified based on its ability to induce production of gamma interferon (IFN-γ) by T cells and enhance natural killer (NK) cell cytolytic activity (23, 38). IL-18 is structurally related to members of the IL-1 family (2) and is processed by IL-1 converting enzyme (ICE) (16, 17). In addition, IL-18 uses an IL-1-like signaling pathway that leads to the activation of NF-κB (31, 52). Although IL-18 is a member of the IL-1 family, it is functionally similar to IL-12. Thus, like IL-12, IL-18 increases production of IFN-γ by NK and T cells (23, 43, 56, 59), augments cytotoxic activity of NK and CD8+ T cells (6, 18), and enhances immunity to tumors and infection (3, 5, 30, 37). Moreover, IL-18-deficient mice have impaired IFN-γ responses following infection with intracellular pathogens (26, 51, 55).

Innate resistance to toxoplasmosis is dependent on the ability of IL-12 to stimulate NK cell production of IFN-γ (15, 22). However, the development of optimal NK cell responses required for resistance to T. gondii is dependent on soluble and cell-bound ligands (CD28, IL-1, and TNF-α) which enhance the IL-12-induced NK cell production of IFN-γ (14, 20, 21, 25, 47). Since NK cells constitutively express the IL-18 receptor (24) and IL-18 is a potent enhancer of NK cell activity and synergizes with IL-12 to stimulate NK cell production of IFN-γ (23, 54, 59), it is a likely candidate to be involved in the regulation of innate resistance to T. gondii. The studies presented here suggest that endogenous IL-18 has a minor role in resistance to T. gondii but demonstrate that exogenous IL-18 can enhance NK cell-mediated resistance to this pathogen.

MATERIALS AND METHODS

Antibodies and cytokines. A two-site enzyme-linked immunosorbent assay (ELISA) was employed to assay levels of IFN-γ as previously described (44).

* Corresponding author. Mailing address: Department of Pathobiology, School of Veterinary Medicine, University of Pennsylvania, 3800 Spruce St., Philadelphia, PA 19104-6008. Phone: (215) 573-7772. Fax: (215) 573-7023. E-mail: chunter@phl.vet.upenn.edu.
Ethanol was used to fix the cells. After fixation, the cells were washed twice and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell counter. Cytotoxicity assays were performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets.PECs or splenocytes from mice were harvested and then washed twice, and the number of viable cells was estimated based on trypan blue exclusion. These cells were plated at different effector:target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytotoxicity assay. Cytotoxicity assays were performed as previously described (53). Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytotoxicity assay. Cytotoxicity assays were performed as previously described (53). Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.

Cytokine assay. Cytokine assay was performed as previously described. Briefly, YAC-1 cells (American Type Culture Collections, Rockville, Md.) were labeled with 100 μCi of 51Cr (Amersham, Arlington Heights, Ill.) for 1 h at 37°C, washed, and used as targets. PECs or splenocytes from mice were harvested and then washed twice, and the number of live cells was estimated based on trypan blue exclusion. These cells were plated at different effector target ratios and incubated at 37°C for 4 h. Supernatants were harvested with a Skatron cell press (Sterling, Va.), the amount of 51Cr released was estimated using a gamma counter (Packard, Meriden, Conn.), and the specific lysis was calculated as previously described.
did not alter the numbers of PECs recovered (isotype control = 4.3 × 10^6 ± 1.2 × 10^6; anti-IL-18 = 5.3 × 10^6 ± 2.1 × 10^6) or the total numbers of splenocytes (isotype control = 7.6 × 10^6 ± 1.3 × 10^6; anti-IL-18 = 8.2 × 10^6 ± 2.2 × 10^6) from mice infected for 5 days. The data presented are the means ± the standard deviations derived from an experiment representative of three experiments performed with three mice per group. Consistent with these results, administration of anti-IL-18 in a single experiment had no effect on the time to death of SCID mice infected with T. gondii (data not shown).

In vitro analysis revealed that splenocytes from infected SCID mice stimulated with TLA produced low levels of IFN-γ, and this was enhanced by the addition of IL-18 or IL-12 (Fig. 3). More- over, the addition of IL-12 plus IL-18 in the presence of TLA resulted in at least two- to threefold-higher levels of IFN-γ compared to either cytokine alone (data not shown). The production of IFN-γ in these cultures was suppressed by the addition of anti-IL-12, and the ability of exogenous IL-18 to enhance production of IFN-γ was reduced by more than 70% when anti-IL-12 was added (Fig. 3). Furthermore, whereas IL-12p40 was readily detectable in cultures stimulated with TLA (ca. 10 ng/ml), IL-18 was not detected. Consistent with these latter results, the addition of anti-IL-18 did not significantly affect the ability of TLA alone or in combination with IL-12 to stimulate the production of IFN-γ (data not shown). These results indicate that the ability of IL-18 to enhance production of IFN-γ in this experimental system is largely dependent on endogenous IL-12. Together with the in vivo studies, these data suggest that endogenous IL-18 has a minor role in regulating the production of IFN-γ required for innate immunity to T. gondii.

Administration of IL-18 enhances innate resistance to T. gondii. Since in vitro studies showed that IL-18 could enhance the parasite-induced production of IFN-γ by splenocytes, IL-18 was administered to SCID mice to determine if this treatment could enhance resistance to T. gondii. Administration of IL-18 to SCID mice 1 day before infection and daily thereafter resulted in a significant decrease in parasite burden on days 10 and 16 postinfection (Fig. 4A) and a 5- to 6-day delay in time to death (Fig. 4B). The total numbers of PECs recovered from mice infected for 16 days and treated with PBS or IL-18 were 15.0 × 10^6 ± 4.2 × 10^6 or 2.17 × 10^6 ± 1.15 × 10^6, respectively, and the total numbers of splenocytes recovered were 26.2 × 10^6 ± 2.5 (PBS) and 61.0 × 10^6 ± 4.2 × 10^6 (IL-18). The data presented are the means ± the SD of a representative experiment of three performed with three mice per group. Note that the numbers of PECs and splenocytes from uninfected SCID mice were typically 1 × 10^6 and 3 × 10^6 to 5 × 10^6, respectively. Immunohistochemical analysis of spleens from infected mice revealed that administration of IL-18 to SCID mice resulted in enhanced expression of iNOS associated with a decreased parasite burden (Fig. 4). Similar results were observed at the local site of infection. Thus, PECs isolated from infected mice treated with IL-18 for 7 days and incubated in medium alone for 24 h produced 38.3 ± 11.3 µM of nitrite, whereas PECs from control infected mice produced <0.1 µM (n = 3 mice per group). In addition, analysis of the number of cysts in the brains of mice on day 16 postinfection revealed that IL-18 treatment resulted in no detectable cysts (n = 3), while control mice treated with PBS had a mean of 4,166 ± 650 cysts (n = 3).

Administration of IL-18 to SCID mice resulted in a significant increase in serum levels of IFN-γ on days 5 and 16 postinfection (Fig. 5). The data shown are the means ± the SD from a single experiment done in triplicate. Similar results were observed in two additional experiments.
Depletion of NK cells in SCID mice treated with IL-18 antagonized the delay in time to death seen in these mice (Fig. 7A). NK cells are thought to be the major source of IFN-γ in SCID mice and, in our studies, depletion of NK cells led to >90% reduction in serum levels of IFN-γ during infection. However, low levels of IFN-γ were detected in NK-depleted, IL-18-treated SCID mice, suggesting either incomplete depletion of NK cells or that there are alternative sources of IFN-γ in SCID mice (12, 34, 57). Nevertheless, depletion of IFN-γ completely inhibited the protective effects of IL-18 (Fig. 7B), and mice died by day 9 postinfection (data not shown). On day 7 postinfection, the total numbers of PECs recovered from mice treated with PBS plus isotype, IL-18 plus isotype, PBS plus anti-IFN-γ, and IL-18 plus anti-IFN-γ were 0.9 × 10⁶, 1.3 × 10⁶ ± 1.2 × 10⁶, 11.6 × 10⁶ ± 2.9 × 10⁶, and 4.4 × 10⁶ ± 2.5 × 10⁶, respectively, and the total numbers of splenocytes of these four groups were 10 × 10⁶ ± 0, 30 × 10⁶ ± 10 × 10⁶, 7.6 × 10⁶ ± 4.3 × 10⁶, and 5.0 × 10⁶ ± 1.4 × 10⁶, respectively. The data shown are the means ± the SD from a representative experiment with three mice per group. Together, these data

To assess the basis for the protective effects of exogenous IL-18, the roles of IL-12, IFN-γ, and NK cells in treated mice were analyzed. Depletion of IL-12 resulted in reduced serum levels of IFN-γ in both IL-18- and PBS-treated mice (Fig. 6A). In addition, our results showed that in the absence of IL-12, both IL-18- and PBS-treated SCID mice showed an increase in the percentage of infected PECs compared to isotype control mice on day 7 postinfection (Fig. 6B). The total numbers of PECs recovered from mice treated with PBS plus isotype, PBS plus anti-IL-12, IL-18 plus isotype, and IL-18 plus anti-IL-12 on day 7 postinfection were 2.7 × 10⁶ ± 2.4 × 10⁶, 9.8 × 10⁶ ± 3.1 × 10⁶, 0.9 × 10⁶ ± 0.7 × 10⁶, and 1.8 × 10⁶ ± 0.4 × 10⁶, respectively, whereas splenocytes from these four groups were 11.0 × 10⁶ ± 1.8 × 10⁶, 3.9 × 10⁶ ± 1.8 × 10⁶, 23.2 × 10⁶ ± 4.5 × 10⁶, and 4.5 × 10⁶ ± 3.1 × 10⁶, respectively. However, mice treated with IL-18 plus anti-IL-12 had fewer parasites than mice treated with anti-IL-12 alone (P < 0.05) (Fig. 6B). This reduction in parasite numbers correlated with a 2- to 3-day delay in time to death (P = 0.0025) (Fig. 6C). These results suggest that, although the protective effects of exogenous IL-18 are largely dependent on endogenous IL-12, there is an IL-12-independent pathway that can enhance resistance to T. gondii.

FIG. 4. Administration of IL-18 to SCID mice enhances resistance to T. gondii. SCID mice infected with T. gondii were treated with IL-18 (200 ng per mouse) or PBS beginning 1 day before infection and daily thereafter. (A) The percentages of PECs infected were calculated as described in Materials and Methods. Results shown are the means ± the SD of four pooled experiments with three to six mice per group (†, P < 0.05). (B) SCID mice were infected with T. gondii and treated daily with PBS or IL-18, and the survival was monitored. The results presented are the pooled data from five independent experiments with a total of 15 mice per experimental group. (C) Immunohistochemical detection of T. gondii and iNOS in the spleens of SCID mice infected for 16 days and treated with PBS or IL-18. Similar results were observed in three other mice.

TABLE 2

<table>
<thead>
<tr>
<th></th>
<th>PECs</th>
<th>Spleen</th>
<th>Total cells (10⁶)</th>
<th>% NK cells</th>
<th>Total cells (10⁶)</th>
<th>% NK cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>PBS</td>
<td>9.0 ±/− 2.6</td>
<td>7.0 ±/− 6.2</td>
<td>9.0 ±/− 5.3</td>
<td>5.9 ±/− 2.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IL-18</td>
<td>1.3 ±/− 0.7</td>
<td>57.0 ±/− 28.0*</td>
<td>10.2 ±/− 2.8</td>
<td>2.8 ±/− 0.7</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FIG. 5. Administration of IL-18 to SCID mice enhances production of IFN-γ and NK cell activity during toxoplasmosis. (A) Serum levels of IFN-γ from SCID mice treated with PBS or IL-18 were measured by ELISA. The results shown are the means ± the SD of four pooled experiments with three to six mice per group (†, P < 0.05). (B) Administration of IL-18 to SCID mice enhances NK cell activity (effector/target ratio = 25) on day 16 postinfection of T. gondii. The data shown are representative of three independent experiments with three mice per group. (C) Effect of administration of IL-18 on NK cell numbers during toxoplasmosis. On day 16 postinfection, the total numbers of NK cells were 1.3 × 10⁶, 1.2 × 10⁶, 1.4 × 10⁶, and 1.8 × 10⁶, respectively.
indicate that IL-18 mediated resistance is dependent on the production of IFN-γ by NK cells.

**DISCUSSION**

Previous studies have shown that infection with *T. gondii* results in increased production of IL-12 that is necessary for NK cell production of IFN-γ required for innate resistance to this pathogen (13, 49, 50). The data presented here demonstrate that, although infection resulted in an increase in serum levels of IL-18, these levels were low compared to other situations in which IL-18 has been shown to have a functional role (17). Accordingly, depletion of endogenous IL-18 during toxoplasmosis resulted in only a transient reduction in levels of IFN-γ and did not significantly affect parasite burden or survival. Thus, despite its functional similarity to IL-12, upregulation of IL-18 following infection appears to have a minor role in innate resistance to *T. gondii*. In support of this conclusion, mice deficient in the ICE (which is involved in the processing and secretion of IL-18) infected with *T. gondii* also have an early defect in their ability to produce IFN-γ but are resistant to toxoplasmosis (G. Cai and C. A. Hunter, manuscript in preparation). Together, these studies suggest a limited role for endogenous IL-18 in T-cell-independent resistance to *T. gondii*. Nevertheless, future studies using IL-18−/− mice will be necessary to confirm our findings on the role of endogenous IL-18 in resistance to toxoplasmosis. Consistent with our findings, other researchers have demonstrated that, during infection with *Salmonella enterica* serovar Typhimurium, endogenous IL-18 has a minor role in the production of IFN-γ required for clearance of this intracellular pathogen (8, 9). Interestingly, *T. gondii* and serovar Typhimurium induce high levels of nitric oxide during the acute stage of infection, and studies by Kim et al. demonstrated that nitric oxide can inhibit the production of IL-18 (28), which may explain the low levels of IL-18 detected following infection with these pathogens. This may be a common mechanism to limit potentially pathogenic immune responses or a strategy for intracellular pathogens to inhibit protective immune responses.

Although endogenous IL-18 does not appear to be critical for innate resistance to *T. gondii*, administration of IL-18 to SCID mice did result in a significant reduction in the parasite burden associated with enhanced production of IFN-γ. In vivo depletion studies revealed that the protective effects of IL-18 were dependent on IL-12, IFN-γ, and NK cells, suggesting that the ability of IL-18 to synergize with IL-12 to stimulate NK cell production of IFN-γ is the basis for the protective effects of exogenous IL-18. In support of this, the administration of IL-18 to uninfected SCID mice, in which there are low levels of endogenous IL-12, did not increase the total number of splenocytes or the NK cell activity or serum IFN-γ levels compared to

**FIG. 6.** IL-18-mediated resistance is dependent on endogenous IL-12. (A) SCID mice were infected with *T. gondii* and treated with IL-18 or PBS alone or in combination with anti-IL-12 or rat IgG. The treatment with anti-IL-12 resulted in complete abrogation of serum levels of IL-12p40 on days 3, 5, and 7 postinfection. The serum levels of IFN-γ on day 5 postinfection were measured by ELISA (A), and the percentage of infected PECs on day 7 postinfection calculated (B) as described in Materials and Methods. The data shown are the means ± the SD of the pooled data from three experiments with three to five mice per group. (C) Effect of depletion of endogenous IL-12 on the survival of SCID mice treated with IL-18. Similar results were observed in a repeat experiment with four mice per group.

**FIG. 7.** IL-18-mediated resistance to *T. gondii* is dependent on NK cells and IFN-γ. (A) SCID mice (*n = 8*) were infected *T. gondii* and treated with IL-18 or PBS alone or in combination with rabbit IgG or rabbit anti-asialoGM1 as described in Materials and Methods, and survival was monitored. Similar results were observed in a repeat experiment. (B) SCID mice were infected with *T. gondii* and treated with IL-18 or PBS alone or in combination with anti-IFN-γ or rat IgG as described in Materials and Methods, and the percentage of infected PECs on day 7 postinfection was estimated. The data shown are the means ± the SD of three pooled experiments with three mice per group.
PBS-treated control mice. In contrast, the administration of IL-18 to infected SCID mice led to an increased percentage of NK cells in the peritoneal cavity, suggesting that IL-18 may enhance the recruitment of NK cells to the local sites. This may be due to the ability of IL-18 to stimulate chemokine production (11) or its ability to upregulate adhesion molecule expression (29). However, these data have to be interpreted with care since many of the treatments used in these studies resulted in large changes in numbers of cells in the peritoneum and spleen. For example, administration of IL-18 to infected mice resulted in a twofold increase in the numbers of spleen cells, but a similar change was not observed at the local site of infection; rather, infected mice treated with IL-18 had sevenfold fewer PECs compared to untreated mice. One interpretation of these data is that these changes may be a function of the immune regulatory effects of exogenous IL-18 and a function of parasite burden. Thus, the immune effects of IL-18 may account for the increase in the numbers of cells in the spleen. In contrast, the lower numbers of inflammatory cells in the peritoneum are likely a reflection of the reduced parasite burden in mice treated with IL-18. This balance between immune regulatory effects and parasite burden could also explain why treatment with anti-IL-12 inhibited expansion of immune populations in the spleen but the 5- to 10-fold increase in parasite numbers in the peritoneum led to a 3-fold increase in the numbers of inflammatory cells at this site. Nevertheless, SCID mice treated with IL-18 still succumbed to toxoplasmosis within 4 weeks, and immunohistochemical analysis revealed that these mice could not control parasite growth in peripheral tissues (lungs, hearts, and brains) but did control parasite replication at the local site of infection and treatment (peritoneal cavity). This contrasts with untreated SCID mice that had large numbers of parasites in the peritoneum at the time they succumb to the infection on day 20. Why IL-18 can protect at the local site of treatment but not in other organs may be explained by the ultimate requirement for T cells for long-term resistance to T. gondii or a restricted ability of IL-18-activated NK cells to traffic to, and mediate protection at, different sites.

There are several reports of an IL-12-independent pathway that allows the generation of IFN-γ-dependent resistance to T. gondii (10, 45), as well as to other intracellular pathogens (27, 40). Our studies suggest that IL-18 can decrease parasite burden and delay time to death of SCID mice treated with anti-IL-12. This IL-12-independent protective effect is likely to be due to the ability of IL-18 alone to stimulate NK cells to produce low levels of IFN-γ (4, 38). Thus, although serum levels of IFN-γ were greatly reduced in mice treated with anti-IL-12, administration of IL-18 to these mice did enhance levels of IFN-γ mRNA in the spleen (data not shown). Furthermore, mice deficient in the transcription factor STAT4 (required for IL-12-mediated signaling) are highly susceptible to toxoplasmosis; administration of IL-18 results in a reduced parasite burden but ultimately fails to protect these mice (G. Cai and C. A. Hunter, submitted for publication). Together, these studies suggest that exogenous IL-18 is a potent enhancer of IL-12-mediated resistance to T. gondii and, although it can enhance resistance to toxoplasmosis independently of IL-12, this is a relatively minor effect.

Recent studies have demonstrated the importance of endogenous IL-18 for enhancing the production of IFN-γ following infection with Leishmania major, Staphylococcus aureus (55), Mycobacterium tuberculosis (48), and murine cytomegalovirus infection (26). However, it appears that endogenous IL-18 is not required for innate resistance to T. gondii (this study) or serovar Typhimurium (9). Thus, although IL-12 and IFN-γ are central mediators of resistance to many of these pathogens (1, 7, 19, 46), the requirement for IL-18 varies between pathogens. In addition, our studies demonstrate that the ability of IL-18 to mediate resistance to T. gondii is largely dependent on endogenous IL-12. Since it has been proposed that IL-18 may be useful for the treatment of infectious diseases (36) and cancer (5, 32, 35, 39), the studies presented here add to our knowledge of the interactions between IL-12 and IL-18 necessary for optimal innate immune responses.

ACKNOWLEDGMENTS

This work was supported by a grant from the NIH (AI42334-01) and center grant P30 DK50306. DNAx is supported by the Schering-Plough Corporation. C.A.H. is a Burroughs Wellcome New investigator in Molecular Parasitology.

REFERENCES


Editor: S. H. E. Kaufmann